What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Evidence from the FREEDOM-2 trial indicates that fedratinib significantly improves spleen volume and symptom response compared to best available therapy, with response rates of 36% and 34% respectively. However, the uncertainty regarding overall survival benefits beyond 6 months limits the rating to moderate benefit.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for fedratinib are within the acceptable range for Healthcare resources, with the EAG’s base-case results indicating an ICER below £30,000 per QALY gained, suggesting it is a cost-effective option.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that fedratinib improves quality of life through symptom reduction, although the exact utility values were not derived from the recommended EQ-5D-3L. The committee acknowledged that even small symptom reductions can enhance quality of life.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Fedratinib has a good safety profile with manageable adverse events. The committee noted that while adverse events exist, they are mostly mild to moderate, indicating acceptable tolerability.
Was the drug compared against what payers expect? — Comparator Selection
The main comparator was best available therapy, which is appropriate. However, the absence of a direct comparison with momelotinib, despite its relevance, limits the robustness of the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is representative of the intended patient population with intermediate-2 or high-risk myelofibrosis. The committee noted that the positioning of fedratinib aligns with clinical practice.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Fedratinib can be integrated into existing treatment pathways with minor adjustments, as it is positioned for use after ruxolitinib and when momelotinib is unsuitable.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact is manageable, and the economic model suggests that fedratinib is resource-efficient, aligning with Healthcare funding capabilities.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is primarily derived from the FREEDOM-2 trial, a Phase 3 RCT, which provides a strong foundation. However, uncertainties in long-term outcomes introduce some limitations.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding long-term survival and treatment discontinuation, which could impact the overall assessment of fedratinib’s effectiveness.
